Table 1. Patient characteristics and comparison with trial participants without available tissue.
| Study sample: tissue available (n=90) | Randomised trial patients: tissue unavailable (n=114) | P-value (χ2) | |
|---|---|---|---|
|
Treatment group |
|
|
0.51 |
| Chemoradiation | 49% | 54% | |
| Chemoradiation+erlotinib |
51% |
46% |
|
|
Sex |
|
|
0.56 |
| Male | 88% | 85% | |
| Female |
12% |
15% |
|
|
Race |
|
|
0.81 |
| White | 82% | 80% | |
| Black or African-American | 16% | 14% | |
| American Indian or Alaska Native | 0% | 1% | |
| Asian | 1% | 3% | |
| Other | 0% | 1% | |
| Unknown |
1% |
1% |
|
|
Ethnicity |
|
|
0.50 |
| Hispanic | 11% | 10% | |
| Not Hispanic | 88% | 90% | |
| Unknown |
1% |
0% |
|
|
Smoking status |
|
|
0.87 |
| Current | 26% | 23% | |
| Former | 51% | 54% | |
| Never |
23% |
23% |
|
|
Primary site |
|
|
0.009* |
| Hypopharynx | 6% | 6% | |
| Larynx | 20% | 16% | |
| Nasopharynx | 2% | 0% | |
| Oral Cavity | 1% | 12% | |
| Oropharynx | 71% | 62% | |
| Overlapping |
0% |
4% |
|
|
T Stage |
|
|
0.09 |
| T1 | 10% | 5% | |
| T2 | 23% | 37% | |
| T3 | 37% | 38% | |
| T4 |
30% |
20% |
|
|
N Stage |
|
|
0.10 |
| N0 | 15% | 6% | |
| N1 | 10% | 18% | |
| N2 | 67% | 69% | |
| N3 | 8% | 7% |
*
Indicates statistical significance.